Tests AVZO-1418 alone or combined in advanced solid tumors
Tests the new drug AVZO-1418 in adults with advanced solid tumors.
Plain-language title generated from the registry record
Registry title: AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Key facts
- Where
- Beijing, Changsha, Chongqing, Harbin, Jinan, Nanchang, Shenyang, and Zhengzhou, ChinaSee the 8 sites
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced or metastatic epithelial solid tumors that can be measured on scans. It tests a new drug, AVZO-1418, for the first time in people.
- Age
- 18 to 75 years
- Sex
- All sexes
- Disease stage
- Locally advanced or metastatic epithelial solid tumor, confirmed by tissue or cell tests, with measurable disease (RECIST v1.1).
- Biomarker or test result
- Patients must agree to provide a molecular test report, plus archival tumor samples and/or a fresh biopsy, as applicable.
Main reasons for not taking part
- Uncontrolled high blood pressure
- Active brain or spinal cord metastases, or leptomeningeal disease
- History of drug-induced interstitial lung disease
- History of any serious heart or blood vessel condition
- History of a solid organ transplant
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07038343, who can take part
Where in China
- Beijing, Beijing MunicipalityHospital not named in the registryContact: DualityBioTaking people
- Changsha, HunanHospital not named in the registryContact: DualityBioTaking people
- Chongqing, Chongqing MunicipalityHospital not named in the registryContact: DualityBioTaking people
- Harbin, HeilongjiangHospital not named in the registryContact: DualityBioTaking people
- Jinan, ShandongHospital not named in the registryContact: DualityBioTaking people
- Nanchang, JiangxiHospital not named in the registryContact: DualityBioTaking people
- Shenyang, LiaoningHospital not named in the registryContact: DualityBioTaking people
- Zhengzhou, HenanHospital not named in the registryContact: DualityBioTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Avenzo Therapeutics, Inc.
- Trial code
- NCT07038343
- Record updated
- 16 October 2026
- Original description
This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy and potentially in combination therapy to patients with locally advanced or metastatic epithelial solid tumors.Read full original descriptionShow less
A Phase 1/2, First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors
This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy and potentially in combination therapy to patients with locally advanced or metastatic epithelial solid tumors.
Inclusion: Patient must be an adult, between 18 and 75 years of age with an Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1 and a life expectancy of > 3 months; Patients with histologically or cytologically confirmed locally advanced/metastatic malignancies for tumor types of preferred indications:; o Locally advanced or metastatic epithelial solid tumors (as specified in the protocol); Measurable disease as assessed by Investigator using RECIST v1.1; Agree to provide molecular test report results to confirm eligibility and archival tumor samples and/or fresh biopsy, as applicable; Other protocol-defined Inclusion criteria apply.
Exclusion: Patients with active central nervous system (CNS) metastases are not eligible. Patients with asymptomatic and treated brain metastases may participate if they are radiologically stable for at least 4 weeks prior to the first dose of this study and do not require steroid treatment. Patients with suspected or confirmed leptomeningeal disease are not eligible, even if treated; Infection requiring IV antibiotics, antivirals, or antifungals within 2 weeks prior to first dose; Uncontrolled hypertension; History of drug-induced interstitial lung disease (ILD); History of any serious cardiovascular condition; History of a solid organ transplant; Other protocol-defined Exclusion criteria apply.